Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old

Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (i.e., LAI-PrEP) was approved by the U.S. FDA in 2021. We sought to explore LAI-PrEP decision-making among a nationwide sample of young sexual minority men (YSMM) 17–24 years old. In 2020, HIV-negative/unknown YSMM (n...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Steven A., Zapata, Juan P., Dang, Madeline, Pleuhs, Benedikt, O’Neil, Andrew, Hirshfield, Sabina, Walsh, Jennifer L., Petroll, Andrew E., Quinn, Katherine G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052280/
https://www.ncbi.nlm.nih.gov/pubmed/36991027
http://dx.doi.org/10.1038/s41598-023-32014-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10052280/
https://www.ncbi.nlm.nih.gov/pubmed/36991027
http://dx.doi.org/10.1038/s41598-023-32014-8

Ejemplares similares